Unité de Fabrication des Médicaments S.A (BVMT: UMED)

Market Cap	225.60M
Revenue (ttm)	141.07M
Net Income (ttm)	6.43M
Shares Out	32.00M
EPS (ttm)	n/a
PE Ratio	35.07
Forward PE	10.68
Dividend	n/a
Ex-Dividend Date	n/a

Volume	948
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	6.17 - 7.57
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 20, 2024

About BVMT: UMED

Unité de Fabrication des Médicaments S.A. develops, manufactures, markets, and sells generic medicines under the UNIMED brand in Tunisia, Africa, Asia, and Europe. The company offers Opthalmic, ENT, and inhalation solutions, infusion solutions, injectable fluids and penicillin, and cephalosporin powders, as well as vaigtaine products in approximately 40 presentations for various therapeutic classes. It manufactures medicines for third party laboratories principals. Unité de Fabrication des Médicaments S.A. was founded in 1989 and is based in So...

• Industry: Pharmaceutical Preparations
• Founded: 1989
• Employees: 572
• Stock Exchange: Tunis Stock Exchange
• Ticker Symbol: UMED

Financial Performance

In 2023, UMED's revenue was 136.00 million, an increase of 41.14% compared to the previous year's 96.36 million. Earnings were 5.55 million, a decrease of -29.17%.